RxDoctor Payments Data

Nicholas Willis, MD

Cardiovascular Disease · Pine Bluff, ARNPI 1629292883

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $10,210 of the $14,649 with a category attached, or 69.7%. 40 manufacturers reported payments, led by Medtronic at 26.7% of the total.

$14,649in general payments, 2019–2025

Across 520 payments — averaging $28.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$4K
  • Penumbra, Inc.$2K
  • Amgen$1K
  • Novartis$1K
  • Merck$559
  • Pfizer$548
  • plus $5K from 34 others

What the payments were for

  • Travel & lodging$4,36330%
  • Food & beverage$10,21070%
  • Education$761%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,649 in reported general payments places this provider in the 85th percentile of 130 cardiovascular disease providers in Arkansas.

See all cardiovascular disease providers in Arkansas

Medicare billing

Part B allowed, 2024
$439,243
Medicare patients
1,476
Services billed
6,849

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban717$599,199
EntrestoSacubitril/Valsartan361$343,140
Repatha SureclickEvolocumab95$121,160
MultaqDronedarone Hcl87$79,716
FarxigaDapagliflozin Propanediol89$62,924
XareltoRivaroxaban76$59,271
BrilintaTicagrelor53$27,995
Ranolazine ErRanolazine341$21,157
WegovySemaglutide15$20,473
Praluent PenAlirocumab17$20,008
OzempicSemaglutide12$15,580
Atorvastatin Calcium1,208$8,695
Olmesartan Medoxomil861$7,917
Nifedipine ErNifedipine496$7,677
Losartan Potassium1,094$6,320

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$548$599,199717 claims
NovartisEntresto$1,180$343,140361 claims
AstraZenecaFarxiga, Brilinta$220$90,919142 claims
Sanofi-aventis U.S. LLCMultaq$242$79,71687 claims
Johnson & JohnsonXarelto$509$59,27176 claims
Novo NordiskWegovy, Ozempic$174$36,05427 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 130 cardiovascular disease providers in Arkansas.

Other cardiovascular disease in Pine Bluff

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →